--- title: "Entrada Therapeutics to cut about 20% of workforce in strategic plan" url: "https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-04-29" section: "Distress" tickers: "NASDAQ:TRDA" source: "https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm" summary: "Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash run" --- By the aibio.space news desk. Sources - [Entrada Therapeutics, Inc. 8-K (2025-04-29)](https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm) - [Entrada Therapeutics, Inc. 10-K (2025-02-27): business](https://www.sec.gov/Archives/edgar/data/1689375/000168937525000011/trda-20241231.htm) [TRDA](https://aibio.space/companies/entrada-therapeutics/) 2025-04-29 # Entrada Therapeutics to cut about 20% of workforce in strategic plan Tickers [TRDA](https://aibio.space/companies/entrada-therapeutics/) Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another. ## Key facts - **Company**: Entrada Therapeutics, Inc. (NASDAQ: TRDA) - **News type**: Distress - **Primary source**: [Entrada Therapeutics, Inc. 8-K (2025-04-29)](https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm) *A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The plan Entrada Therapeutics, Inc. (Nasdaq: [TRDA](https://aibio.space/companies/entrada-therapeutics/)) said in an 8-K that its board approved a strategic plan on April 29, 2025. The plan takes effect May 2, 2025. It pairs enhanced hiring for planned global clinical trials in Duchenne muscular dystrophy with focused workforce reductions in select research areas. The company expects those reductions to cut its workforce by about 20%. The filing gives no headcount. The company expects the reduction to be substantially complete by the end of the second quarter of 2025. ## The cost Entrada expects aggregate charges of about $2 million for the reduction. They consist mainly of one-time severance payments and continued healthcare benefits for a set period, and most are expected in the second quarter of 2025. The company also says it may incur other charges or cash expenditures that it cannot estimate now. The filing names no figure for those, and it does not quantify the cost savings the plan is meant to produce. ## What the company is prioritizing Entrada says it is focusing on four Duchenne candidates, ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51, along with its ocular programs and platform investments. Duchenne is caused by mutations in the DMD gene that lead to a failure to produce enough functional dystrophin, a protein needed to keep muscle cells intact. The lead candidate, ENTR-601-44, had its FDA clinical hold lifted on February 24, 2025, and the company received authorization to start a Phase 1b multiple ascending dose study in adult DMD patients. The company plans to start enrollment in that study in the first half of 2026. A separate UK Phase 1/2 study of the same drug was authorized in February 2025, and the company said it was on track to start that trial in the second quarter of 2025. The company's annual report for 2024 said it expected four clinical programs in patients by the end of 2025. Its partnered candidate, VX-670, is in a global Phase 1/2 trial run by Vertex Pharmaceuticals Incorporated. Vertex announced in November 2024 that it had finished the Phase 1 single ascending dose portion and started the Phase 2 multiple ascending dose portion. ## The platform The company's EEV platform uses small cyclic peptides of about 10 amino acids or fewer to carry therapeutics into cells. In preclinical studies, the company reports that more than 90% of EEV-conjugated material is taken up by tissues, and that about 50% escapes the early endosome to reach its target. Those are the company's own preclinical figures. The annual report points to positive preliminary data in healthy volunteers from a Phase 1 trial reported in 2024, not to results in patients. It says the company is on track to submit applications for ENTR-601-50 in the fourth quarter of 2025, expects global filings for ENTR-601-51 in 2026, and expects to share its first ocular clinical candidate later in 2025. ## What the filing leaves open The 8-K says the cash runway extends into the second quarter of 2027. Its forward-looking statements say the company expects its cash resources to last into the second half of 2027. The two phrases differ, and the filing does not reconcile them. The 8-K gives no cash balance. Chief Executive Officer Dipal Doshi signed the 8-K. The company is based in Boston, Massachusetts, and reports as an emerging growth company. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story TRDA Entrada Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Entrada Therapeutics to cut about 20% of workforce in strategic plan", 2025-04-29, https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/